Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial

International Journal of Urology

Volumn 9, Issue 3, 2002, Pages 162-166

  Sousa Escandón, Alejandro ^b,d   Vazquez, Sergio ^a   Quintero Aldana, Guillermo ^c   Apicallo, Jose ^b   Neira, Javier ^b   Garcia Novio, Francisco ^b   Teo, Ama ^b   Rico, Manuel ^b   Mel, Jose R ^c  

^a Hopital Comarcal de Monforte   (Spain)

^b Pneumology Unit   (Spain)

^c Polusa Hospital   (Spain)

^d Hospital Comarcal de Monforte   (Spain)

Author keywords

Chemotherapy; Cisplatin; Neo adjuvant treatment; Paclitaxel; Toxicity; Transitional bladder cancer

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY TESTING; TRANSITIONAL CELL CARCINOMA; VOMITING;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOADJUVANT THERAPY; PACLITAXEL; THROMBOCYTOPENIA; URINARY BLADDER NEOPLASMS;

EID: 0036090888     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00443.x     Document Type: Article

References (17)

1. Cancer statistics, 1997
2. Review and outlook for the role of pacli-taxel in urothelial carcinoma
3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse
4. Chemotherapy for invasive bladder cancer
5. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
6. Chemotherapy of urothelial tract tumors
7. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial
8. Escalated MVAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors
9. Dose-intensification of methotrexate, vinblastine, doxorubicin, and cisplatin with recombinant granulocyte-colony stimulating factor as initial therapy in advanced urothelial cancer
10. Should single agents be standard therapy for urothelial tract tumors?
11. Escalated dosages of methotrexate, vinblastine, doxorubicin and cisplatine plus rh-G-CSF in advanced urothelial carcinoma: An ECOG trial
12. Palliative chemotherapy in advanced bladder cancer
13. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology group
14. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy
15. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: A phase II trial
16. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
17. A phase II trial of Ifosfamide and paclitaxel in advanced transitional cell carcinoma of the urothelium